Trial Profile
Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Pharmacokinetics
- Acronyms PROFILE
- Sponsors Astellas Pharma Europe Ltd
- 27 Sep 2018 Results published in the Journal of Antimicrobial Chemotherapy
- 14 Nov 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.